Background: Urothelial bladder carcinomas had traditionally been difficult to treat cancers,
with high morbidity and mortality rates when invasive and metastatic. In recent years …

Background Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …

The increasing incidence of urothelial bladder cancer is a notable global concern, as
evidenced by the epidemiological data in terms of frequency, distribution, as well as …

Background: Phase I and II studies suggest potential benefit with targeted therapy (TT)(eg,
FGFR3, ERBB2/3 and CDK4/6 inhibitors) in relevant molecular subsets of MUC. Given …

Pembrolizumab was recently approved for treatment of cancers with high tumor mutational
burden (TMB). We conduct a focused literature review of TMB as a predictive biomarker …

Purpose Urothelial carcinoma of the bladder (UCB) is a common malignancy with limited
systemic treatment options in advanced stages. Despite recent advances in immunotherapy …

To explore the prognosis of tumor mutation burden (TMB) and underlying relationships with
tumor‐infiltrating immune cells in bladder cancer (BLCA). Transcriptome profiles and …

Simple Summary In recent years, there have been several advances in the care of advanced
bladder cancer, highlighted by the addition of immune checkpoint inhibitors to the care of …

Bladder cancer is a leading cause of morbidity and mortality worldwide. Currently,
immunotherapy has become a worthwhile therapy for bladder cancer. Tumor mutation …

Bladder cancer is a heterogeneous disease, which exhibits a wide spectrum of clinical and
pathologic features. Recent genomic studies have revealed that distinct molecular …